Not SuperKLOW in different packaging — a different formulation
The usual approach to a women's version of anything in this category is to keep the formula and change the label. Wonder Woman shares a backbone with our men's stack and then differs in four substantive ways: one peptide removed entirely, one doubled, and two added specifically because the research supporting them was done in women or in the experimental model of menopause.
Two of its doses are not reasoned from mechanism at all. They are the doses used in the human trials, which is a rarer thing in this market than it should be.
Four differences, each with a reason
| Component | Men's stack | Wonder Woman | Why |
|---|---|---|---|
| BPC-157 | 500 mcg/day | Removed entirely | A small number of female users report emotional blunting |
| Thymosin α-1 | 250 mcg/day | 500 mcg/day — doubled | Thymic decline is described as accelerating at menopause |
| Tesamorelin | — | 1.0 mg/day — added | Baker 2012 cognitive trial, 59% female cohort |
| MOTS-c | — | 1.33 mg/day — added | Lu 2019 — prevented ovariectomy-induced metabolic dysfunction |
| Ipamorelin | — | 333 mcg on M1b | Second GH pathway, alternating with Epitalon |
BPC-157 is not in this vial
BPC-157 is one of the most widely used regenerative peptides in existence and it is in our men's stack. It is absent here for one reason: a small number of female users report emotional blunting and anhedonia on it — a flattening rather than a low mood — possibly through dopamine pathway modulation.
It is a minority report and we cannot point to a trial establishing it. We removed the compound anyway. When the reports concern something as difficult to notice and as unpleasant to live with as emotional flatness, the burden of proof runs the other way — we would rather formulate around a risk we cannot rule out than argue with the people describing it.
The regenerative side is covered by GHK-Cu at 2 mg daily and the TB-4 active fragment at 667 mcg, both unchanged from the men's stack. Nothing was left thin to accommodate the removal.
Thymosin α-1, at twice the men's dose
The thymus produces the peptides that mature T-cells, and it shrinks with age — thymic involution. Research describes that decline as accelerating around menopause, which is the rationale for supplying more of it to exactly the group in which the endogenous production is falling fastest.
At 500 mcg daily this comes to 3.5 mg a week. The clinical dose of the pharmaceutical form — sold as Zadaxin — is 1.6 mg twice weekly, or 3.2 mg a week. Our weekly exposure is deliberately set alongside the clinical figure rather than at a token inclusion level. Thymosin α-1 is also among the most expensive actives we buy, which is precisely why it is the one most often present in name only elsewhere.
Two compounds chosen because the evidence was female
Tesamorelin — at the trial dose, on the trial schedule
Baker and colleagues (Archives of Neurology, 2012) ran a randomised, double-blind, placebo-controlled trial of tesamorelin in 152 adults aged 55–87, 66 of them with mild cognitive impairment. The cohort was 59% women. Participants received 1 mg daily, subcutaneously, thirty minutes before bedtime for twenty weeks. Reported outcome: a positive effect on cognition (P = .03), improvement in executive function, with benefit in both the impaired and the healthy older participants.
Our dose is 1.0 mg daily. Not approximately — the same figure, by the same route. Where a human trial has established a dose in a population that includes the people you are formulating for, using a different number requires a reason, and we did not have one.
MOTS-c — tested in the model of menopause
Lu and colleagues (Journal of Molecular Medicine, 2019) examined MOTS-c in ovariectomised mice — the standard experimental analogue of menopause, where falling oestrogen drives fat accumulation and disrupts adipose function until insulin resistance follows. MOTS-c treatment was reported to prevent both the obesity and the insulin resistance: increased brown fat activation, reduced fat accumulation and inflammatory invasion of white adipose tissue, lower serum and liver fatty acids, and AMPK activation. The authors concluded it was a strong candidate for chronic treatment of menopause-induced metabolic dysfunction.
That is a targeted intervention against a specific, well-described metabolic shift — not a general wellness peptide included because it sounds mitochondrial. It is in this vial and not the men's stack for exactly that reason.
Why it ships as M1a and M1b
The two vials are identical apart from a single 5 mg component. M1a carries Epitalon; M1b carries Ipamorelin. Everything else — all 90 mg of the backbone — is the same.
Epitalon is cycled rather than run continuously: fifteen days on, forty-five off. Research describes chronic uninterrupted dosing as potentially downregulating the telomerase pathway it acts on, so continuous use would work against the reason for taking it. Across a sixty-day rotation that means one M1a vial and three M1b vials.
Splitting it across two vials makes the cycling structural rather than optional. You cannot accidentally run Epitalon continuously, because the vial in your hand physically does not contain any. That is the whole reason for the format — a protocol that depends on someone remembering to stop is a protocol that will be got wrong.
On the Epitalon-off weeks the slot is not left empty. Ipamorelin takes it — a selective ghrelin-receptor agonist that triggers GH release through a different receptor family from tesamorelin, without the cortisol or prolactin elevation reported for older secretagogues. Since tesamorelin is present daily throughout, the M1b weeks are running dual-pathway GH stimulation.
Seven actives, 95 mg, fifteen daily doses
| Active | Per vial | Per day | Role |
|---|---|---|---|
| GHK-Cu | 30 mg | 2.0 mg | Copper tripeptide — ECM remodelling, collagen, dermal density, hair |
| MOTS-c | 20 mg | 1.33 mg | Mitochondrial peptide — AMPK; validated against ovariectomy-induced decline |
| Tesamorelin | 15 mg | 1.0 mg | GHRH analogue — cognition, visceral fat, IGF-1 |
| TB-500 fragment | 10 mg | 667 mcg | Cell migration, angiogenesis, soft tissue repair |
| Thymosin α-1 | 7.5 mg | 500 mcg | Immune modulation — T-cell maturation, NK activity |
| KPV | 7.5 mg | 500 mcg | Anti-inflammatory tripeptide — NF-κB, TNF-α, IL-6 |
| Epitalon (M1a) / Ipamorelin (M1b) | 5 mg | 333 mcg | The one component that alternates — see cycling |
At roughly 255 mOsm/kg this sits just below plasma — a mild, comfortable injection despite carrying seven actives and more than six milligrams of peptide per dose. The reason is molecular weight: peptides are large, so considerable mass contributes very little osmotically. It is the same arithmetic that makes a small-molecule product sting at a fraction of the load.
One peptide removed on the strength of user reports we could not verify. Two added because the trials behind them were run in women. That is what a female-optimised formulation ought to mean.
All custom blends